
|Articles|September 18, 2014
- Melanoma (Issue 3)
- Volume 3
- Issue 1
Partnering T-VEC With a Targeted Agent for the Treatment of Melanoma
Author(s)Igor Puzanov, MD
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Advertisement
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the potential to partner T-VEC with a targeted agent for the treatment of patients with melanoma.
Learn about targeted agents for the treatment of melanoma > >
Articles in this issue
about 11 years ago
Inducing an Immune Response With a Patient’s Tumorabout 11 years ago
Immunotherapy Combinations for the Treatment of MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































